What's Happening?
The upcoming 2026 Joint Review of the United States-Mexico-Canada Agreement (USMCA) presents an opportunity to address vulnerabilities in North America's pharmaceutical supply chains. The COVID-19 pandemic highlighted the region's reliance on foreign
suppliers for active pharmaceutical ingredients (APIs) and finished drugs, particularly from China and India. The review aims to propose cooperative reforms to enhance regional resilience and competitiveness. Key proposals include regulatory harmonization, mutual recognition of good manufacturing practice inspections, and the establishment of a North American supply chain security council. This council would coordinate policy, monitor vulnerabilities, and advise on crisis response, similar to the European Union's Health Emergency Preparedness and Response Authority (HERA). The review also considers Mexico's role as a nearshoring hub, leveraging its cost advantages and proximity to the U.S. market.
Why It's Important?
Strengthening pharmaceutical supply chains in North America is crucial for economic and public health security. The region's dependence on foreign suppliers poses risks of supply disruptions, as seen during the COVID-19 pandemic. By enhancing regional cooperation, the USMCA can reduce these vulnerabilities and ensure a more resilient supply chain. This is particularly important as geopolitical tensions and climate-related disruptions threaten global supply networks. A coordinated approach could also balance innovation with affordability, addressing disparities in drug pricing across the region. The review's outcomes could influence U.S. industrial policy, potentially shifting focus from unilateral tariffs to regional incentives for production, thereby avoiding consumer cost increases and trade tensions.
What's Next?
The 2026 USMCA Joint Review will likely lead to policy recommendations aimed at strengthening North American pharmaceutical supply chains. These may include creating a shared early-warning system for drug shortages and investing in API and generic drug production capacity within the region. The review's findings could also impact the forthcoming Section 232 national security review of the pharmaceutical sector, which is expected to evaluate the feasibility of global tariffs on APIs and finished drugs. The success of these initiatives will depend on the ability of the USMCA partners to harmonize regulatory frameworks and coordinate investments, ensuring that pharmaceutical resilience remains a sustained priority.
